Symbols / CURX $0.41 +7.87%

CURX Chart
About

Curanex Pharmaceuticals Inc, a developmental stage pharmaceutical company, discovers, develops, and commercializes botanical drugs to treat patients suffering from inflammatory diseases. It develops Phyto-N for various therapeutic areas, including ulcerative colitis, atopic dermatitis, COVID-19, diabetes, nonalcoholic fatty liver disease, and gout. The company was formerly known as Fordman Pharma Inc. and changed its name to Curanex Pharmaceuticals Inc in November 2023. Curanex Pharmaceuticals Inc was founded in 1996 and is headquartered in Jericho, New York.

Fundamentals
Scroll to Statements
Sector Healthcare Industry Biotechnology Market Cap 11.62M
Enterprise Value 19.13M Income -435.03K Sales —
Book/sh 0.01 Cash/sh 0.00 Dividend Yield —
Payout 0.00% Employees — IPO —
P/E — Forward P/E — PEG —
P/S — P/B 31.54 P/C —
EV/EBITDA — EV/Sales — Quick Ratio 1.43
Current Ratio 9.37 Debt/Eq 155.99 LT Debt/Eq —
EPS (ttm) -0.02 EPS next Y — EPS Growth —
Revenue Growth — Earnings — ROA -30.03%
ROE -85.25% ROIC — Gross Margin 0.00%
Oper. Margin 0.00% Profit Margin 0.00% Shs Outstand 28.34M
Shs Float 8.91M Short Float 0.67% Short Ratio 0.03
Short Interest — 52W High 9.18 52W Low 0.28
Beta — Avg Volume 224.88K Volume 478.51K
Target Price — Recom None Prev Close $0.38
Price $0.41 Change 7.87%
Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
—
Mean price target
2. Current target
$0.41
Latest analyst target
3. DCF / Fair value
$-0.32
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$0.41
Low
—
High
—
Mean
—
News
RSS: Latest CURX news
Insider Transactions

No recent insider transactions.

Financials
Line Item2024-12-312023-12-312022-12-31
TaxEffectOfUnusualItems0.000.000.00
TaxRateForCalcs0.000.000.00
NormalizedEBITDA-215.71K-17.48K925.00
TotalUnusualItems-74.68K0.00
TotalUnusualItemsExcludingGoodwill-74.68K0.00
NetIncomeFromContinuingOperationNetMinorityInterest-361.51K-19.20K-20.23K
ReconciledDepreciation0.001.81K21.16K
ReconciledCostOfRevenue0.0021.57K
EBITDA-290.39K-17.48K925.00
EBIT-290.39K-19.30K-20.23K
NormalizedIncome-286.83K-19.20K-20.23K
NetIncomeFromContinuingAndDiscontinuedOperation-361.51K-19.20K-20.23K
TotalExpenses290.39K19.30K46.23K
TotalOperatingIncomeAsReported-365.06K-19.30K-20.23K
DilutedAverageShares27.75M42.00M42.00M
BasicAverageShares27.75M42.00M42.00M
DilutedEPS-0.01-0.00-0.02
BasicEPS-0.01-0.00-0.02
DilutedNIAvailtoComStockholders-361.51K-19.20K-20.23K
NetIncomeCommonStockholders-361.51K-19.20K-20.23K
NetIncome-361.51K-19.20K-20.23K
NetIncomeIncludingNoncontrollingInterests-361.51K-19.20K-20.23K
NetIncomeContinuousOperations-361.51K-19.20K-20.23K
PretaxIncome-361.51K-19.20K-20.23K
OtherIncomeExpense-71.12K100.00
OtherNonOperatingIncomeExpenses3.56K100.00
SpecialIncomeCharges-74.68K0.00
ImpairmentOfCapitalAssets74.68K0.00
OperatingIncome-290.39K-19.30K-20.23K
OperatingExpense290.39K19.30K24.66K
SellingGeneralAndAdministration290.39K19.30K24.66K
GeneralAndAdministrativeExpense290.39K19.30K24.66K
OtherGandA290.39K19.30K24.66K
GrossProfit0.004.43K
CostOfRevenue0.0021.57K
TotalRevenue0.000.0026.00K
OperatingRevenue0.000.0026.00K
Line Item2024-12-312023-12-312022-12-31
OrdinarySharesNumber27.75M27.75M27.75M
ShareIssued27.75M27.75M27.75M
TangibleBookValue503.26K60.09K10.23K
InvestedCapital503.26K60.09K10.23K
WorkingCapital503.36K60.09K10.23K
NetTangibleAssets503.36K60.09K10.23K
CommonStockEquity503.26K60.09K10.23K
PreferredStockEquity100.00
TotalCapitalization503.36K60.09K10.23K
TotalEquityGrossMinorityInterest503.36K60.09K10.23K
StockholdersEquity503.36K60.09K10.23K
OtherEquityInterest200.00K200.00K200.00K
RetainedEarnings-622.45K-260.94K-241.75K
AdditionalPaidInCapital923.31K120.97K51.88K
CapitalStock2.50K60.00100.00
CommonStock2.40K60.00100.00
PreferredStock100.000.000.00
TotalLiabilitiesNetMinorityInterest14.57K14.28K0.00
TotalNonCurrentLiabilitiesNetMinorityInterest0.000.000.00
CurrentLiabilities14.57K14.28K0.00
PayablesAndAccruedExpenses14.57K14.28K0.00
CurrentAccruedExpenses9.55K13.68K0.00
Payables5.03K600.00
TotalTaxPayable25.00600.000.00
AccountsPayable5.00K0.00
TotalAssets517.93K74.37K10.23K
TotalNonCurrentAssets0.000.000.00
CurrentAssets517.93K74.37K10.23K
OtherCurrentAssets367.87K1.81K
CurrentDeferredAssets367.87K0.00
PrepaidAssets1.18K0.00
Inventory0.002.99K
Receivables0.003.00K
DuefromRelatedPartiesCurrent0.003.00K
CashCashEquivalentsAndShortTermInvestments148.89K74.37K2.43K
CashAndCashEquivalents148.89K74.37K2.43K
CashFinancial148.89K74.37K2.43K
Line Item2024-12-312023-12-312022-12-31
FreeCashFlow-555.58K-120.003.34K
IssuanceOfCapitalStock630.10K69.06K0.00
EndCashPosition148.89K74.37K2.43K
BeginningCashPosition74.37K2.43K2.09K
ChangesInCash74.53K71.94K336.00
FinancingCashFlow630.10K72.06K-3.00K
CashFlowFromContinuingFinancingActivities630.10K72.06K-3.00K
NetOtherFinancingCharges3.00K-3.00K
NetPreferredStockIssuance100.000.00
PreferredStockIssuance100.000.00
NetCommonStockIssuance630.00K69.06K0.00
CommonStockIssuance630.00K69.06K0.00
OperatingCashFlow-555.58K-120.003.34K
CashFlowFromContinuingOperatingActivities-555.58K-120.003.34K
ChangeInWorkingCapital-268.75K17.26K2.41K
ChangeInOtherCurrentLiabilities0.00-19.16K
ChangeInOtherCurrentAssets-267.87K0.00
ChangeInPayablesAndAccruedExpense299.0014.28K0.00
ChangeInAccruedExpense-4.70K14.28K0.00
ChangeInPayable5.00K
ChangeInAccountPayable5.00K0.00
ChangeInPrepaidAssets-1.18K0.00
ChangeInInventory0.002.99K21.57K
AssetImpairmentCharge74.68K
DepreciationAmortizationDepletion0.001.81K21.16K
DepreciationAndAmortization0.001.81K21.16K
Depreciation0.001.81K21.16K
NetIncomeFromContinuingOperations-361.51K-19.20K-20.23K
SEC Filings

Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.

Public Trades for CURX
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status